These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24323690)

  • 81. Minimally invasive transcrestal sinus floor elevation with deproteinized bovine bone or β-tricalcium phosphate: a multicenter, double-blind, randomized, controlled clinical trial.
    Trombelli L; Franceschetti G; Stacchi C; Minenna L; Riccardi O; Di Raimondo R; Rizzi A; Farina R
    J Clin Periodontol; 2014 Mar; 41(3):311-9. PubMed ID: 24325663
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Cellular interactions and bone healing responses to a novel porous tricalcium phosphate bone graft material.
    Fredericks DC; Bobst JA; Petersen EB; Nepola JV; Dennis JE; Caplan AI; Burgess AV; Overby RJ; Schulz OH
    Orthopedics; 2004 Jan; 27(1 Suppl):s167-73. PubMed ID: 14763552
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Macroporous calcium phosphate ceramic: a prospective study of 106 cases in lumbar spinal fusion.
    Cavagna R; Daculsi G; Bouler JM
    J Long Term Eff Med Implants; 1999; 9(4):403-12. PubMed ID: 10847976
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Use of 3D beta-tricalcium phosphate (Vitoss) scaffolds in repairing bone defects.
    Damron TA
    Nanomedicine (Lond); 2007 Dec; 2(6):763-75. PubMed ID: 18095844
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Reply to the Letters to the editor: Safety in surgery and overall health: what is the responsibility of the patient?
    Lee MJ
    Clin Orthop Relat Res; 2014 Sep; 472(9):2897-8. PubMed ID: 24980640
    [No Abstract]   [Full Text] [Related]  

  • 86. Letter to the editor: Safety in surgery and overall health: what is the responsibility of the patient?
    Woo EJ
    Clin Orthop Relat Res; 2014 Sep; 472(9):2893-4. PubMed ID: 24973086
    [No Abstract]   [Full Text] [Related]  

  • 87. Letter to the editor: Safety in surgery and overall health: what is the responsibility of the patient?
    DiCuccio M
    Clin Orthop Relat Res; 2014 Sep; 472(9):2895-6. PubMed ID: 24964890
    [No Abstract]   [Full Text] [Related]  

  • 88. Letter to the editor: in vitro elution characteristics of vancomycin in a composite calcium phosphate/calcium sulfate bone substitute.
    Al Khudairy A; Phelan JP
    HSS J; 2014 Feb; 10(1):98. PubMed ID: 24482630
    [No Abstract]   [Full Text] [Related]  

  • 89. Letter to editor in reference to OT-RADS.
    Chhabra A
    Skeletal Radiol; 2023 Apr; 52(4):771-772. PubMed ID: 36260153
    [No Abstract]   [Full Text] [Related]  

  • 90. Letter to editor: Covid-19 and dealing with it-lessons learned in Iran.
    Maziar P; Razavi S; Hosseini Ghavamabad L
    Med J Islam Repub Iran; 2020; 34():110. PubMed ID: 33316015
    [No Abstract]   [Full Text] [Related]  

  • 91. Letter to the editor regarding 'Immediate lymphatic reconstruction: Lessons learned over eight years'.
    Mehranjani AA
    J Plast Reconstr Aesthet Surg; 2024 Sep; 96():223-224. PubMed ID: 39096739
    [No Abstract]   [Full Text] [Related]  

  • 92. Reply to the letter to the editor by R. Papke.
    Exner M; Bhattacharya S; Gebel J; Goroncy-Bermes P; Hartemann P; Heeg P; Ilschner C; Kramer A; Ling ML; Merkens W; Oltmanns P; Pitten F; Rotter M; Schmithausen RM; Sonntag HG; Steinhauer K; Trautmann M
    GMS Hyg Infect Control; 2021; 16():Doc23. PubMed ID: 34354902
    [No Abstract]   [Full Text] [Related]  

  • 93. Injectable Synthetic Beta-Tricalcium Phosphate/Calcium Sulfate (GeneX) for the Management of Contained Defects Following Curettage of Benign Bone Tumours.
    Razii N; Docherty LM; Halai M; Mahendra A; Gupta S
    Curr Oncol; 2023 Mar; 30(4):3697-3707. PubMed ID: 37185394
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Treatment of benign bone lesions with an injectable biphasic bone substitute.
    Döring K; Rentenberger C; Kolb A; Patsch J; Puchner S; Windhager R; Chiari C
    BMC Musculoskelet Disord; 2022 Oct; 23(1):901. PubMed ID: 36209080
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Reply to the Letter to the Editor: Adverse reactions of artificial bone graft substitutes: lessons learned from using tricalcium phosphate geneX ®.
    Friesenbichler J; Maurer-Ertl W; Sadoghi P; Pirker-Fruehauf U; Bodo K; Leithner A
    Clin Orthop Relat Res; 2014 Feb; 472(2):767-8. PubMed ID: 24323690
    [No Abstract]   [Full Text] [Related]  

  • 96. Adverse reactions of artificial bone graft substitutes: lessons learned from using tricalcium phosphate geneX ®.
    Laycock PA; Cooper JJ
    Clin Orthop Relat Res; 2014 Feb; 472(2):765-6. PubMed ID: 24323689
    [No Abstract]   [Full Text] [Related]  

  • 97. Adverse reactions of artificial bone graft substitutes: lessons learned from using tricalcium phosphate geneX®.
    Friesenbichler J; Maurer-Ertl W; Sadoghi P; Pirker-Fruehauf U; Bodo K; Leithner A
    Clin Orthop Relat Res; 2014 Mar; 472(3):976-82. PubMed ID: 24078171
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Dangers of bone graft substitutes: lessons from using GeneX.
    Saadoun S; Macdonald C; Bell BA; Papadopoulos MC
    J Neurol Neurosurg Psychiatry; 2011 Aug; 82(8):e3. PubMed ID: 21386107
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Calcium sulfate- and calcium phosphate-based bone substitutes. Mimicry of the mineral phase of bone.
    Tay BK; Patel VV; Bradford DS
    Orthop Clin North Am; 1999 Oct; 30(4):615-23. PubMed ID: 10471766
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Nonallograft osteoconductive bone graft substitutes.
    Bucholz RW
    Clin Orthop Relat Res; 2002 Feb; (395):44-52. PubMed ID: 11937865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.